Motivated from a colorectal cancer study, we propose a class of frailty semi-competing risks survival models to account for the dependence between disease progression time, survival time, and treatment switching. Properties of the proposed models are examined and an efficient Gibbs sampling algorithm using the collapsed Gibbs technique is developed. A Bayesian procedure for assessing the treatment effect is also proposed. The deviance information criterion (DIC) with an appropriate deviance function and Logarithm of the pseudomarginal likelihood (LPML) are constructed for model comparison. A simulation study is conducted to examine the empirical performance of DIC and LPML and as well as the posterior estimates. The proposed method is further applied to analyze data from a colorectal cancer study.
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Introduction
In chronic disease or cancer studies and clinical trials, it is very common to have both terminating events and nonterminating events in the data. This type of situation is referred as semi-competing risks, in which an event time can be censored by another event time but not vice versa. A terminating event potentially censors a nonterminating event, but the nonterminating event does not prevent subsequent observation of the terminating event. An example of this is the colorectal cancer clinical trial that we examine here, called the panitumumab 408 study, which was conducted by Amgen Inc (see Sect. 5) . In this study, disease progression is a nonterminating event, death is a terminating event, and disease progression can be censored by death but not vice-versa. In addition to semi-competing risks, treatment switching may also occur in clinical trials. In such trials, patients in the control arm who experience an intermediate event, such as disease progression, may begin taking the experimental treatment. In the panitumumab 408 study, there were a substantial proportion of patients in the control arm who switched treatment after disease progression (see Sect. 5). As discussed in Marcus and Gibbons (2011) , an intent-to-treat (ITT) analysis leads to attenuated treatment effect estimates, and thus one must properly model the data accommodating this switching effect and then appropriately estimate the treatment effect.
In semi-competing risks data, there are two major issues: dependent censoring and identifiability. In order to deal with these issues, several modeling and inference approaches have been developed. One major approach is to model the joint distribution of T D and T E , where T D denotes the time to terminating event and T E denotes the time to nonterminating event. Day and Bryant (1997) used frailty models for the joint survival function using a relevant censoring process. Later, Fine et al. (2001) adopted this model and proposed a novel estimator for the marginal distribution of T E based on a bivariate location-shift model with a completely unspecified underlying distribution for T D and T E . Although this method is appropriate for modeling one recurrent event taking into account dependent censoring, it cannot be applied to more than two recurrent events. Furthermore, various types of copula models have been applied for modeling the joint distribution of (T E , T D ) (Wang 2003; Ghosh 2006; Peng and Fine 2007) . Another approach is to model the gap time T G between T D and T E (Mandel 2010) . Nonparametric estimation of the gap time distribution and regression methods for gap time hazard functions have been developed. A third approach is similar to the above gap time model. In addition to modeling T E and T G , another event time T * D is introduced, which denotes the terminating event that happens without the nonterminating event T E . Shen and Thall (1998) used such a model for obtaining the marginal distributions of T E , T G and T * D . They assumed that the distributions of T E and T * D are mutually independent. For the bivariate distribution of T E and T G , they used a bivariate generalized von Morgenstern distribution, which characterizes the positive or negative association between these two times using a single parameter. A conditional model is also developed (Zeng et al. 2012) . Instead of modeling the joint distribution of T E and T G , a conditional model of T G given T E is used. Multistate modeling is another approach for survival data with semi-competing risks, in which no event, nonterminating event, and terminating event can be viewed as the three states in a multistate process. The focus of multistate modeling is mainly on the transition probabilities between different states. Aalen-Johansen estimators (Aalen 1978; Andersen et al. 1993) can be used to estimate these transition probabilities. However, this approach does not provide much information on the dependence structure between the time to nonterminating event and the time to terminating event. Except for Zeng et al. (2012) , most of the aforementioned articles do not directly deal with both semi-competing risks and treatment switching.
In this paper, we introduce a Bayesian frailty model for survival data with semicompeting risks in the presence of partial treatment switching (i.e., not every subject in the control arm switched to active treatment). In the frequentist inference, the Monte Carlo EM (MCEM) algorithm is often used to obtain the maximum likelihood estimates in the presence of the unobserved frailty variables. However, the MCEM algorithm may fail to converge when fitting a semi-competing risks frailty model with unknown parameters in the frailty distribution since the estimates of these unknown parameters are unstable. To overcome this challenging computational issue, we develop an efficient Gibbs sampling algorithm via the introduction of latent variables, reparameterization, and the collopsed Gibbs sampler. The Bayesian framework also allows us to characterize the conditions for model identifiability by examining posterior propriety. In addition, to appropriately estimate the treatment effect, we extend the method of Zeng et al. (2012) to derive the predictive survival function with partial treatment switching under the semi-competing risks frailty model and carry out Bayesian inference on this quantity without resorting to asymptotics.
The rest of the paper is organized as follows. Section 2 presents a detailed development of the semi-competing risks model via a gamma frailty including explicit expressions for the likelihood function based on the observed data. In Sect. 3, we characterize posterior propriety conditions under this complex model, provide the Bayesian formulation of the predictive survival function with partial treatment switching, develop an efficient Gibbs sampling algorithm, and introduce two Bayesian model comparison criteria. A simulation study is carried out to examine the empirical performance of the posterior estimates and Bayesian model criteria in Sect. 4, and a detailed analysis of a subset of the data from the panitumumab 408 study is presented in Sect. 5. We conclude the paper with a brief discussion in Sect. 6. The proofs of all theorems and detailed derivations of the computational development are given in the Appendices.
The semi-competing risks frailty models

Models
To introduce the proposed model, we use the following notation. As motivated from the panitumumab 408 study, we consider disease progression as a nonterminating event. However, the proposed model can be applied to any other type of nonterminating event. Let E be a dichotomous variable to denote the disease progression status of subjects, where E = 1 if the subject is in the disease progression population, which include subjects who eventually develop disease progression before death, and E = 0 if otherwise. Also let T D denote the time from study entry to death for subjects with E = 0. For the disease progression population (E = 1), we further let T E denote the time from study entry to disease progression and let T G denote the time from disease progression to death. A graphical illustration of these variables is shown in Fig. 1 . The proposed statistical model consists of the following three components. The first component is to model the disease progression status E given the baseline covariates x and the treatment indicator A (A = 1 if the subject is on the treatment arm and A = 0 if the subject is on the placebo or control arm). To this end, we assume
where α 0 , α 1 , and α 2 are unknown coefficients and α = (α 0 , α 1 , α 2 ) . The second component models the survival distribution of the non-progression population given x and A, which is defined by
2)
where h D (t|A, x, E = 0) is the conditional hazard function of T D given the covariates, h 0 (t) is an unknown baseline hazard function, and (β 0 , γ 0 ) are unknown regression coefficients. As shown in Fig. 1 , T E and T G are potentially dependent. To capture this dependence, we assume the frailty model
is the conditional hazard function for T G , both h 1 (t) and h 2 (t) are unknown baseline hazard functions, and the β's and γ 's are regression coefficients. Here, V is the treatment switching indicator (1 = switching; 0 = no switching) and z reflects the covariates collected at baseline or at disease progression, which could be prognostic factors for the treatment switching decision. In (2.3), ω is a latent gamma-frailty, which is assumed to follow a Gamma distribution, Gamma(1/τ, 1/τ ), with mean one, variance τ (τ > 0), and density given by f (ω|τ ) = (1/τ ) 1/τ (1/τ ) ω 1/τ −1 exp(−ω/τ ). Given ω, T E and T G are conditionally independent. Unconditionally, T E and T G are dependent and, moreover, the local measure of dependence (Oakes 1989) between T E and T G is φ FM = 1 + τ , indicating a positive association between T E and T G . When τ → 0, φ FM → 1 and T E and T G become independent. The model defined by (2.1) -(2.3) is thus called the semi-competing risks frailty model abbreviated by FM. As an alternative to (2.3), we may consider the following models for T E and T G :
where γ 21 is the regression coefficient corresponding to T E and γ 22 is the corresponding vector of regression coefficients associated with z. The model defined by (2.1), (2.2), and (2.4) is called the conditional semi-competing risks model, denoted by CM. After some algebra, we can show that the local measure of dependence between T E and T G under CM is given by
It is easy to see that φ CM > 1 when γ 21 < 0, φ CM = 1 when γ 21 = 0, and φ CM < 1 when γ 21 > 0. This result implies that CM allows a positive or negative association between T E and T G . As discussed in Zhao (2009) , FM is a homogeneous Markov model when h 2 (t) is constant while CM is a homogeneous semi-Markov model since the hazard function for T G in (2.4) depends on the progression time T E . On the other hand, the marginal distributions of T E and T G after integrating out the gamma frailty belong to the class of generalized odds-rate hazards (GORH) models (see Banerjee et al. 2007) . As the GORH model is a non-proportional hazards model, FM is more robust to the proportional hazards assumption than CM.
We further assume piecewise exponential models for the baseline hazard functions h 0 (t), h 1 (t), and h 2 (t). For k = 0, 1, 2, let s k0 = 0 < s k1 < s k2 < · · · < s k J k be a finite partition of the time axis. Thus, we have the J k intervals:
In the j th interval, we assume a constant baseline hazard, h k (y|λ k ) = λ k j for y ∈ (s k, j−1 , s k j ]. Letting λ k = (λ k1 , λ k2 , . . . λ k J k ) , the cumulative baseline hazard function corresponding to h k (t) is given by
λ kg (s kg − s k,g−1 ) when s k, j−1 < y ≤ s k j for k = 0, 1, 2.
Likelihood function
Suppose we have n subjects. Let y i denote the observed death time or censoring time, x i is the vector of baseline covariates, A i is the treatment indicator, y Ei is the observed disease progression time, z i is the vector of covariates collected at baseline or at disease progression, and V i is the indicator for treatment switching for the i th subject for i = 1, . . . , n. Also let ν i be the censoring variable such that ν i = 1 if y i is a death time and ν i = 0 if y i is a right censoring time, and let d i be the indicator variable such that d i = 1 if y Ei is a disease progression time and 0 if there is no disease progression for the i th individual. When d i = 0, y Ei is assumed to be equal to infinity. Finally, we use E i to denote the disease progression indicator such that E i = 1 if subject i is in the disease progression population and 0 otherwise. Let P(
and ω i is a latent frailty for the i th subject. Based on the nature of the semi-competing risks, the observations in the observed data can be classified into four different cases. Under FM, the likelihoods for these four cases are derived as follows.
Case 1. Subject died at time y i and no disease progression was observed. Then we have E i = 0, d i = 0 and ν i = 1 and the observation is
The likelihood function is given as follows:
Case 2. Subject was observed to have disease progression at y Ei and died at y i . Then we have E i = 1, d i = 1, and ν i = 1, and the observation is
. Case 3. Subject was observed to have disease progression at y Ei and right censored at y i . Then we have E i = 1, d i = 1, and ν i = 0, and the observation is
Case 4. Subject was only observed to be right censored at y i and no disease progression occurred before y i . Then we have d i = 0 and ν i = 0 and the observation is
and for such a subject, it is possible that E i = 1 or E i = 0. The likelihood function is given by
. . , n) denote the observed data, where D i is defined by (2.5)-(2.8). Then, the observed-data likelihood function under FM is given by
where 1{B} denotes the indicator function such that 1{B} = 1 if B is true and 0 other-
The likelihood under CM can be derived in a similar way. Specifically, under CM,
Posterior inference and computation
Prior and posterior distributions
Let θ = (α , β 0 , γ 0 , λ 0 , β 1 , γ 1 , λ 1 , β 2 , γ 2 , λ 2 , τ ) denote the vector of all the model parameters. To carry out a Bayesian analysis, we need to specify a prior distribution for θ . We assume that α, (β 0 , γ 0 ), (β 1 , γ 1 ), (β 21 , β 22 , γ 2 ), λ 0 , λ 1 , λ 2 and τ are independent, a priori, and the following priors are specified for these parameters:
where p a , p 0 , p 1 , and p 2 are the dimensions corresponding to the respective vectors of the model parameters, and a , 0 , 1 , 2 , and (a τ , b τ ) are pre-specified hyperparameters.
, and π 2λ (λ 2 ) denote the above prior distributions, respectively. Then, the joint prior of θ is given by π
In the simulation study in Sect. 4 and the analysis of the real data from a colorectal cancer study in Sect. 5, these hyperparameters were specified as a = 1000I p a , 0 = 1000I p 0 , 1 = 1000I p 1 , 2 = 1000I p 2 , a τ = b τ = 0.01, and a k j = b k j = 0 for j = 1, . . . , J k and k = 0, 1, 2, where I p a , I p 0 , I p 1 , and I p 2 are the identity matrices. Using (2.9) and π(θ ), the posterior distribution of θ given the observed data D obs under FM is of the form π(θ|D obs ) ∝ L(θ |D obs )π(θ ).
(3.1)
When π(θ ) is proper, the posterior distribution π(θ |D obs ) is also proper. However, even when π(θ) is improper, the posterior distribution can still be proper under certain mild conditions. To formally establish posterior propriety in this case, let N j denote the set which consists of subjects who were in Case j and n j = |N j |, which is the total number of subjects in Case j for j = 1, . . . , 4, respectively. Write
We are led to the following theorem.
Theorem 1 Assume π a (α) ∝ 1, π 0 (β 0 , γ 0 ) ∝ 1, π 1 (β 1 , γ 1 ) ∝ 1, π 2 (β 2 , γ 2 ) ∝ 1, and a k j = b k j = 0 for j = 1, . . . , J k and k = 0, 1, 2. If the following conditions are satisfied: (i) X a is of full rank; (ii) there exists a positive vector c = (c 1 , . . . , c n * ) ∈ R n 1 +n 2 +n 3 , i.e., each component c i > 0, such that X a c = 0; (iii) X 0 , X 1 , and X 2 are of full rank; and (iv) a τ > 0 and b τ > 0, then the joint posterior π(θ|D obs ) in (3.1) is proper, i.e., L(θ|D obs )π(θ)dθ < ∞.
The proof of Theorem 1 is given in Appendix 1. When a k j = b k j = 0 for j = 1, . . . , J k and k = 0, 1, 2, we specify improper (Jeffreys's) priors for all the λ jk 's, namely, π kλ (λ k j ) ∝ 1 λ k j for j = 1, . . . , J k and k = 0, 1, 2. Conditions (i) and (ii) ensure posterior propriety for α, Condition (iii) leads to the posterior propriety of (λ 0 , β 0 , γ 0 ) and Conditions (iii) and (iv) are required for the posterior propriety of (λ 1 , β 1 , γ 1 , λ 2 , β 2 , γ 2 , τ ). Condition (iii) is quite mild and essentially requires that at least one event (death or disease progression) occurs in each interval (s k, j−1 , s k j ], and the corresponding covariate matrix is of full rank. These conditions are easily satisfied in most applications and are quite easy-to-check.
The predictive survival function with partial treatment switching
An inferential research goal in this research is to compare the survival function of the death time in the setting when no subjects have switched treatment. Let T * D (a) denote a potential survival time when a subject receives treatment a at the time of randomization and stays on the same treatment over the entire study duration. Let S a (t|θ) = P(T * D (a) > t|θ). Following Zeng et al. (2012) , we state the following two assumptions: (i) Treatment A is completely randomized and T * D (a) = T D (a) if a subject never switches treatment; and (ii)
We note that these two assumptions are only used to compute S a (t|θ). Similar to Zeng et al. (2012) , under Assumptions (i) and (ii), we have
is the conditional density of X given A = a, and f Z (z | A = a, x, E = 1) is the conditional density of Z given A = a, x, and E = 1. When J 0 = J 1 = J 2 = 1, after some algebra, we obtain
A detailed derivation of (3.3) is given in Appendix 2. We assume nonparametric
. Since S a (t|θ) is a function of θ, the posterior estimates of S a (t|θ) can be easily obtained using the MCMC samples from the posterior distribution of θ.
Posterior computation
Due to the complexity of the likelihood structure for the proposed frailty model, an analytical evaluation of the posterior distribution is not possible. In order to carry out posterior inference, we develop an efficient Gibbs sampling algorithm to sample θ from the posterior distribution in (3.1). We first consider the transformation
After the transformation, the posterior distribution of θ * is given by
To facilitate the posterior computation, we introduce two sets of latent variables E * = (E * i , i ∈ N 4 ) and w = (w 1 , w 2 , . . . , w n ) so that the augmented posterior distribution of (θ * , E * , w) is given by
It can be shown that E * π(θ * , w, E * |D obs )dw = π(θ * |D obs ), which is given by (3.4). We note that the latent variables (the w i 's) in (3.5) are different than those ω i 's in (2.6)-(2.8).
Let [A|B] denote the conditional distribution of A given B. To run the Gibbs sampling algorithm, we sample from the following conditional distributions in turn: D obs ]. For (ii), we use the modified collapsed Gibbs technique (Liu 1994; Chen et al. 2000) . It is easy to show that
For (ii), following Chen et al. (2000) and using (3.6), we run a sub-Gibbs sampling algorithm to draw from the following conditional distributions:
Next, we will only discuss the properties of the conditional distribution [τ |β 1 , γ 1 , λ * 1 , β 2 , γ 2 , λ * 2 , E * , D obs ] and how to sample τ from this conditional distribution. All other conditional distributions are discussed in detail in Appendix 2. We first consider the transformation τ * = 1/τ . Then, the conditional posterior density of τ * is given by
Then we have (i) the conditional density of τ * given by (3.7) is log-concave; and (ii) the mode of (3.7) is analytically available and given bŷ
The proof of Theorem 2 is given in Appendix 1.
The
j=1 a k j − 3 > 0 ensures the logconcavity and the existence of the mode. This assumption is quite mild. As long as there are more than three patients with disease progression, this assumption still holds even when the improper priors with a τ = 0 and a k j = 0 for all k and j are specified for τ and the λ jk 's. With the log-concavity property, τ * can be exactly drawn from the conditional distribution in (3.7) using the adaptive rejection algorithm of Gilks and Wild (1992) . After τ * is generated, we let τ = 1/τ * and then the value of τ is a sample from the conditional distribution [τ |β 1 , γ 1 , λ * 1 , β 2 , γ 2 , λ * 2 , E * , D obs ] in (iic). With the analytical form of the mode, the performance of the rejection algorithm can be improved substantially as the algorithm does not need to search for the mode.
Model comparison
To carry out Bayesian model comparison, we consider the deviance information criterion (DIC) and the Logarithm of the Pseudo Marginal Likelihood (LPML). We define the deviance Dev(θ ) = −2 log L(θ|D obs ), where L(θ|D obs ) is the observed-data likelihood defined in (2.9). Letθ and Dev = E Dev(θ )|D obs denote the posterior mean of θ and Dev(θ ), respectively. According to Spiegelhalter et al. 2002 , the DIC measure is defined as DIC = Dev(θ ) + 2 p D , where p D = Dev − D(θ ) is the effective number of model parameters. The smaller the DIC value, the better the model fits the data. LPML is another useful Bayesian measure of goodness-of-fit statistic, which is defined based on the Conditional Predictive Ordinate (CPO). For the i th observation, we define CPO as CPO i = L(θ|D i )π(θ |D (−i) )dθ , where D i is the observed data defined in Sect. 2.2, L(θ |D i ) is the observed likelihood for the i th subject, which is the term inside the product in (2.9), D (−i) is the data with D i deleted, and π(θ|D (−i) ) is the posterior density of θ based on the data D (−i) . According to Ibrahim et al. 2001 , LPML = n i=1 log(CPO i ). The larger the LPML value, the better the model fits the data.
A simulation study
To examine the empirical performance of the posterior estimates and DIC and LPML, we carry out a simulation study. Five hundred simulated data sets with n = 500 as well as n = 1, 000 were generated. In the simulation study, the baseline treatment A was generated from a Bernoulli(0.5), corresponding to a randomized trial with a 1 : 1 sample size allocation; two baseline covariates X 1 and X 2 were independently generated from a U (−1, 1) and a Bernoulli(0.6), respectively. Given A and (X 1 , X 2 ), E was generated from model (2.1) with the coefficients (including an intercept) being 1.6, -1.8, 1, and 0.1, respectively. When E = 0, we simulated T D from model (2.2) with H 0 (t) = t, β 0 = −1 and (γ 01 , γ 02 ) = (1, 0.2). For E = 1, we first generated ω from a Gamma(1/τ, 1/τ ) with τ = 1. Then, T E was generated from model (2.3) with H 1 (t) = 5t, β 1 = −0.5 and (γ 11 , γ 12 ) = (1, 0) and an additional prognostic factor Z at disease progression was generated from a U (0, 10) while the selection into treatment switching (V ) for a subject in the control arm (A = 0) was from a Bernoulli( p), where p = exp(−0.
. Moreover, T G was generated from the model in (2.3) with H 2 (t) = t, β 21 = −0.3, β 22 = −0.5, and γ 21 = −0.5, γ 22 = 0.5, γ 23 = −0.4. Finally, the censoring time was generated from a U (1, 7) and the study duration was T * = 3. The latter yielded the average proportions of Cases 1 to 4 as 23 %, 39 %, 19 %, and 18 %.
For each simulated dataset, we fit the proposed FM with various values of (J 0 , J 1 , J 2 ) and computed DIC and LPML. The mean values of the DICs and LPMLs over the 500 simulated datasets were 2986.22 and −1493.24 for (J 0 , J 1 , J 2 ) = (1, 1, 1); 2998.05 and −1499.39 for (J 0 , J 1 , J 2 ) = (5, 5, 5); and 3013.21 and −1507.22 for (J 0 , J 1 , J 2 ) = (10, 10, 10). We note that the true value of (J 0 , J 1 , J 2 ) is (1, 1, 1). Thus, both DIC and LPML correctly identified the true model. Under the best combination of (J 0 , J 1 , J 2 ), namely, (1, 1, 1), the average of the posterior means (EST), and the average of the posterior standard deviations (SD), the simulation standard error (SE), the root of the mean squared error (RMSE), and the coverage probability (CP) of the 95 % highest posterior density (HPD) intervals for each parameter as well as S a (t|θ) were computed. The results are given in Table 1 . Table 1 shows excellent empirical performance of the posterior estimates for all the parameters as well as the survival probabilities for both n = 500 and n = 1000. In particular, the ESTs are nearly identical to the true values, the SDs are very close to the SEs, and the CPs are very close to 95 %. For each simulated dataset, we also fit CM as discussed in Sect. 2.1 and computed the corresponding DIC and LPML for (J 0 , J 1 , J 2 ) = (1, 1, 1) . The box plots of the DIC and LPML differences between CM and FM are shown in Fig. 2. From this figure, we see that all of the DIC differences are above 0 and all LPML differences are below 0, indicating that the frailty model fits the data better than the conditional model for all 500 simulated data sets, which is expected since the data were generated from the frailty model. These results further empirically confirm that FM is indeed quite different from CM, and DIC and LPML are two effective Bayesian model comparison measures for identifying the true models.
Analysis of the panitumumab study
We carry out here a detailed analysis of a subset of the data from the panitumumab study (PMAB408) conducted by Amgen Inc. (Van Cutsem et al. 2007; Amado et al. 2008) . PMAB408 was an open label, randomized, phase III multicenter study designed to compare the efficacy and safety of panitumumab plus best supportive care (P + BSC) versus BSC alone in subjects with EGFr-expressing metastatic colorectal cancer who had documented disease progression during or after prior standard treatment with fluoropyrimidine, irinotecan, and oxaliplatin chemotherapy. Subjects were randomly assigned to receive P + BSC (treatment) or BSC (control). The baseline covariates include initial treatment (P + BSC vs. BSC), age in years at screening, baseline Eastern Cooperative Oncology Group (ECOG) score (score 0 or 1 versus ≥ 2 (bECOG01)), primary tumor diagnosis type (rectal versus colon (Rectal)), gender, and region (western Europe (WesternEU), eastern and central Europe (CenEstEU), and rest of the world). In the subset of the data, there were 223 and 231 patients in the control and treatment arms, respectively. There were 424 subjects who died (208 and 207 in the control and treatment arms, respectively), 387 subjects (201 and 186 in the control and treatment arms, respectively) who developed disease progression, and 59 subjects (18 and 41 in the control and treatment arms, respectively) who died without disease progression. The median age was 62.5 years with interquartile range (55, 69) years. There were 388 patients with ECOG score 0 or 1, 287 were males, 151 had rectal cancer, 352 were from Western Europe, 39 were from Eastern and Central Europe, and 63 were from the rest of the world. The median follow-up time was 189.5 days and the interquartile range of the follow-up time was (93, 334) days. Among those 387 patients who developed disease progression, the median disease progression time is 53 days and the interquartile range is (45, 84) days. Of these 201 patients who developed disease progression in the control arm, 167 patients were switched to the treatment arm at the time of disease progression. The model for the time in months to disease progression includes all the baseline covariates. Among the 387 patients who developed disease progression, the median age at the time of disease progression was 62.1 years with interquartile range (55.0, 69.1), the numbers of patients who had partial response, stable disease, and progressive disease were 19, 86, and 282, respectively. There were 348 patients with baseline ECOG score 0 or 1, 286 patients had a last ECOG score on or prior to disease progression 0 or 1, and 180 patients had grade 2 or above adverse events. The covariates for the time in months from disease progression to death include treatment, bECOG01, age at disease progression, best tumor response with partial response (BTR PR) or stable disease (BTR SD) versus progressive disease according to investigator assessment, last ECOG score on or prior to disease progression (score 0 or 1 versus ≥ 2 (LECOG01)), and adverse events (AE). We fit both FM and CM with different values of J 0 , J 1 and J 2 to the panitumumab data. The DIC and LPML values are given in Table 2 . We see from Table 2 that (J 0 , J 1 , J 2 ) = (1, 30, 5) achieves the smallest DIC value and the largest LPML value among the 7 combinations of (J 0 , J 1 , J 2 ) considered here under both FM and CM and the best DIC and LPML values were 3475.27 and −1741.32 under FM and 3482.62 and −1746.76 under CM, respectively . We also observe that for each of these seven combinations of (J 0 , J 1 , J 2 ), FM consistently has a smaller DIC value and a larger LPML value than CM, implying that FM fits the panitumumab data better than CM. Table 3 shows The treatment switching variable, V , is also associated with T G . The posterior mean and 95 % HPD interval for τ were 0.322 and (0.163, 0.490), which implies that there is a moderate dependence between T E and T G . We also fit the best CM with (J 0 , J 1 , J 2 ) = (1, 30, 5) to the panitumumab data and the posterior mean and 95 % HPD interval for γ 21 in (2.4) were −0.083 and (−0.161, −0.008), which implies that there is a positive association between T E and T G . Panel (a) in Fig. 3 shows the estimated differences of the survival probabilities and their pointwise 95 % confidence intervals (CIs) between the two treatment groups of P + BSC and BSC using the intent-to-treat (ITT) Kaplan-Meier approach and Panel (b) plots the posterior estimates, E S 1 (t|θ)− S 0 (t|θ)|D obs ], where S 0 (t|θ) and S 1 (t|θ) are given in (3.2), and the corresponding pointwise 95 % HPD intervals of S 1 (t|θ)−S 0 (t|θ) between these two treatment groups. From Panel (a) of Fig. 3 , we see that the ITT approach yields no difference between two treatment groups as all 95 % CIs contain 0. In contrast, as shown in Panel (b) of Fig. 3 , all the posterior estimates of S 1 (t|θ) − S 0 (t|θ) are above 0 and the corresponding 95 % HPD intervals are above 0 after 2.25 months. We note that the maximum estimated difference E S 1 (t|θ) − S 0 (t|θ)|D obs ] was attained at approximately 9 months and the corresponding posterior mean and 95 % HPD interval were 0.165 and (0.110, 0.227). These posterior estimates indicate that P + BSC does yield a higher survival probability than BSC. In all of the Bayesian computations, we used 20,000 Gibbs samples after a burn-in of 1000 for each model to compute all the posterior estimates, including posterior means, posterior standard deviations, and 95 % HPD intervals. Codes were written for the FORTRAN 95 compiler using IMSL subroutines with double precision accuracy. The convergence of the Gibbs sampler was checked using several diagnostic procedures discussed in Chen et al. (2000) . The autocorrelations for all model parameters disappeared before lag 10.
Discussion
In this paper, we have proposed a novel semi-competing risks Bayesian frailty model that accommodates treatment switching and dependence between the progression time and survival time. This type of scenario arises often in clinical trials in which, once a patient experiences an event, such as progression, they immediately switch to the experimental treatment. As a result of the switch, the model attempts to capture the treatment effect when no subjects would have switched treatment. The innovation in Using (2.9), it is easy to show that
To prove propriety of the posterior, it is sufficient to show (a) L a (α|D obs )dα < ∞; (b)
Under Conditions (i) and (ii), Theorem 2.1 of Chen and Shao (2001) directly leads to (a). Let j i be an index such that s 0, j i −1 < y i ≤ s 0 j i . Then we have δ i0 j = 1 for j = j i and δ i0 j = 0 for j = j i and (7.4) where M 1 > 0 is a constant. Consider the transformation ξ 0 j = log(λ 0 j ), where dξ 0 j = dλ 0 j λ 0 j for j = 1, . . . , J 0 . Under condition (iii), there exist J 0 + p 0 distinct i 1 , . . . , i J 0 + p 0 ∈ N 1 such that the (J 0 + p 0 ) × (J 0 + p 0 ) matrix X * 0 , which has rows (δ i 01 , . . . , δ i 0 J 0 , A i , x i ) for = 1, . . . , J 0 + p 0 , is of full rank. Using (7.4), we have (7.5) where M 12 > 0 is a constant and ξ 0 = (ξ 01 , . . . , ξ 0 J 0 ) . Now, we take a one-to-one transformation φ 0 = (φ 01 , . . . , φ 0,J 0 + p 0 ) = X * 0 (ξ 0 , β 0 , γ 0 ) . Using (7.5), we have (7.6) where M 13 > 0 is a constant, which completes the proof of (b). For (c), we first rewrite (7.2) as follows: (7.8) and
. Let j i denote the index such that s 2, j i −1 < y Gi ≤ s 2, j i . Then, we have L 2b (β 21 , β 22 , γ 2 , λ 2 |D obs , β 1 , γ 1 , λ 1 , τ )
(7.9)
Observing that (1 + r v) 1+ 1 r ≥ 1 + v for all r > 0 and v > 0, we obtain
Under condition (iii), X 2 is of full rank. Therefore, there exist J 2 + p 2 distinct i 1 , . . . , i J 2 + p 2 ∈ N 2 such that the (J 2 + p 2 ) × (J 2 + p 2 ) matrix X * 2 , which has rows (δ i 21 , . . . , δ i 2J 2 , A i , z i ) for = 1, . . . , J 2 + p 2 , is of full rank. Let N 21 = {i 1 , . . . , i J 2 + p 2 } and N 22 = N 2 − N 21 . Using (7.10), we have L 2b (β 21 , β 22 , γ 2 , λ 2 |D obs , β 1 , γ 1 , λ 1 , τ )
where M 21 > 0 is a constant. Similar to (7.5) and (7.6), using (7.11), we can show that
where M 22 and M 23 are two positive constants. Now, using (7.2), (7.3), (7.7), and (7.12), we obtain
The right hand side of (7.13) is precisely the kernel of the posterior distribution of (β 1 , γ 1 , λ 1 , τ ) 2007), we can show that the integration of the right hand side of (7.13) over (β 1 , γ 1 , λ 1 , τ ) is finite, which completes the proof of Theorem 1.
given byτ * =
. The reasons are as follows: with b τ > 0, b k j > 0 and λ * k j > 0, it is obvious that B 1 < 0; and with the previous assumption that n i=1 [1{ν i = 1, d i = 1}+1{ν i = 0, d i = 1}]+a τ + 2 k=1 J k j=1 a k j −3 > 0, then B 2 > 0, so we have (B 1 + B 2 + B 3 ) 2 − 4B 1 B 2 > 0. Therefore, the equation has two roots. Since τ * > 0, then we only keep the positive solutionτ * since the other root is negative. Since we just showed that the conditional density of τ * given by (3.7) is log-concave, it follows that the mode of (3.7) is analytically available and given bŷ τ * .
Appendix 2: Computational development
A2.1: Derivation of the potential survival function
After some algebra, we obtain
For the more general case, where the values of J 0 , J 1 and J 2 are not specified, we have A = a, x, E = 1, β 1 , γ 1 , λ 1 , ω) 
Before the next derivation, we need to align the partitions of the time axis for h 1 and h 2 . Let 0 < s 3,1 < s 3,2 < cdots < s 3,J 3 be the ordered distinct values of s k,J k , where k = 1, 2. For a given time point t, there exists j t such that t ∈ (s 3, j t −1 , s 3, j t ). In order to facilitate the computation, let s 3,J 3 +1 = s 3,J 3 , s 3,J 3 = s 3,J 3 −1 , . . . , s 3, j t = t.
Then the corresponding constant hazards for each interval are as follows:
, then there exist j l and j u such that (t − s 3, j ) ∈ (s 3, j l −1 , s 3, j l ] and (t − s 3, j−1 ) ∈ (s 3, j u −1 , s 3, j u ]. Let r = j u − j l . Then the range of r is from 0 to J 3 . Therefore, when r = 0, we have
Then ω Q j f (ω | τ )dω = λ 31 j exp(Aβ 1 +x γ 1 ) λ 32 j u exp{Aβ 21 +V (1 − A)β 22 +z γ 2 }−λ 31 j exp(Aβ 1 +x γ 1 )
When r ≥ 1, we have In the posterior computation section, a series of conditional posterior distributions are listed. Now we will show how to sample from these distributions.
(i) [λ 0 , λ * 1 , λ * 2 |β 0 , γ 0 , β 1 , γ 1 , β 2 , γ 2 , w, E * , D obs ]. It is easy to see that conditional on (β 0 , γ 0 , β 1 , γ 1 , β 2 , γ 2 , w, E * , D obs ), (λ 0 , λ * 1 , λ * 2 ) are independent. Therefore, the conditional distributions can be sampled separately. Let δ ik j = 1 if the i th subject failed or was censored in the j th interval for j = 1, 2, ldots J k and 0 otherwise. It can be shown that (ia) [λ 0 j |β 0 , γ 0 , E * , D obs ] ∼ Gamma(a π 0 j , b π 0 j ), where a π 0 j = n i=1 [δ i0 j 1{d i = 0, ν i = 1}] + a 0 j , and b π 0 j = s 0, j−1 <y i ≤s 0 j (y i − s 0, j−1 ) exp(A i β 0 + x i γ 0 )[1{d i = 0, ν i = 1} + (1 − E * i )1{d i = 0, ν i = 0}] + y i >s 0 j (s 0, j − s 0, j−1 ) exp(A i β 0 + x i γ 0 )[1{d i = 0, ν i = 1} + (1 − E * i )1{d i = 0, ν i = 0}] + b 0 j ); (ib) [λ * 1 j |β 1 , γ 1 , w, E * , D obs ] ∼ Gamma(a π 1 j , b π 1 j ), where a π 1 j = n i=1 δ i1 j [1{d i = 1, ν i = 1} + 1{d i = 1, ν i = 0}] + a 1 j , and b π 1 j = s 1, j−1 <y i ≤s 1 j w i (y i − s 1, j−1 ) exp(A i β 1 + x i γ 1 )[1{d i = 1, ν i = 1} + 1{d i = 1, ν i = 0} + E * i 1{ν i = 0, d i = 0}] + y i >s 1 j w i (s 1, j − s 1, j−1 ) exp(A i β 1 + 
